ImmunityBio

Update in progress

IBRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ImmunityBio, Inc. is a San Diego-based biotechnology company developing next‑generation immunotherapies that aim to harness and sustain the patient’s immune response against cancer and infectious diseases. Its platforms cover biologics, including cytokine fusion proteins, DNA/vaccine vectors, and cell therapies, with first‑in‑human agents planned for liquid and solid tumors. Lead candidate Anktiva is used with BCG for BCG‑unresponsive bladder cancer; 3M‑052 is a synthetic TLR7/8 agonist. The company collaborates with NCI, Serum Institute, and BeOne; licenses with 3M IPC and Access to Advanced Health Institute.

Company score

Sentiment: 0.56; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.45; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive